Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

CRBP

Corbus Pharmaceuticals Holdings Inc

Jun 14 • 04:00PM ET

50.10

Dollar change -2.79
Percentage change -5.28	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF ITOT HRTS IWC FESM CANC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.97	Insider Own	1.24%	Shs Outstand	10.69M	Perf Week	13.53%
Market Cap	535.57M	Forward P/E	-	EPS next Y	-4.98	Insider Trans	-	Shs Float	10.55M	Perf Month	13.50%
Income	-33.76M	PEG	-	EPS next Q	-1.38	Inst Own	91.59%	Short Float	3.50%	Perf Quarter	14.70%
Sales	0.00M	P/S	-	EPS this Y	48.33%	Inst Trans	-80.73%	Short Ratio	1.52	Perf Half Y	768.28%
Book/sh	9.23	P/B	5.43	EPS next Y	6.51%	ROA	-38.06%	Short Interest	0.37M	Perf Year	533.38%
Cash/sh	11.26	P/C	4.45	EPS next 5Y	-	ROE	-59.52%	52W Range	3.03 - 55.41	Perf YTD	729.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.86%	ROI	-33.82%	52W High	-9.58%	Beta	2.62
Dividend TTM	-	Quick Ratio	4.69	Sales past 5Y	76.56%	Gross Margin	-	52W Low	1551.61%	ATR (14)	3.94
Dividend Ex-Date	-	Current Ratio	4.69	EPS Y/Y TTM	42.53%	Oper. Margin	0.00%	RSI (14)	59.85	Volatility	9.19% 9.29%
Employees	19	Debt/Eq	0.18	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	79.33
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	80.44%	Payout	-	Rel Volume	1.07	Prev Close	52.89
Sales Surprise	-	EPS Surprise	23.85%	Sales Q/Q	-	Earnings	May 07 BMO	Avg Volume	242.59K	Price	50.10
SMA20	9.33%	SMA50	19.73%	SMA200	138.28%	Trades		Volume	260,151	Change	-5.28%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-03-24	Reiterated	Oppenheimer	Outperform	$60 → $80
May-13-24	Initiated	RBC Capital Mkts	Outperform	$77
Mar-06-24	Upgrade	Jefferies	Hold → Buy	$4 → $46
Sep-08-20	Downgrade	ROTH Capital	Buy → Neutral	$40 → $3
Sep-08-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-08-20	Downgrade	Jefferies	Buy → Hold	$18 → $2.50
Sep-08-20	Downgrade	BTIG Research	Buy → Neutral
Jul-07-20	Initiated	ROTH Capital	Buy	$40
Jun-17-20	Initiated	BTIG Research	Buy	$22
Mar-26-20	Initiated	Nomura	Buy	$12
Apr-05-19	Initiated	Jefferies	Buy
Mar-20-19	Initiated	Oppenheimer	Outperform	$28
Jan-11-19	Reiterated	Cantor Fitzgerald	Overweight	$36 → $38
Dec-26-18	Initiated	H.C. Wainwright	Buy	$24
Dec-07-18	Initiated	RBC Capital Mkts	Outperform	$23
Oct-24-18	Initiated	B. Riley FBR	Buy	$22
Jan-19-18	Initiated	Raymond James	Outperform	$24
Dec-14-17	Reiterated	Cantor Fitzgerald	Overweight	$24 → $28
Nov-08-17	Reiterated	Noble Financial	Buy	$16 → $20
Sep-29-17	Resumed	Noble Financial	Buy	$16

Show Previous Ratings

Jun-01-24 10:00AM	SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024 (GlobeNewswire)
May-30-24 08:00AM	Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-23-24 05:05PM	Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting (GlobeNewswire) -7.96%
May-17-24 04:12PM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
May-09-24 08:00AM	Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
01:52PM	Loading…
May-07-24 01:52PM	CRBP Stock Earnings: Corbus Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
08:17AM	Corbus Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-06-24 02:06PM	How the Medical Industry Could Produce the Biggest AI Stock Winners (InvestorPlace)
May-01-24 08:00AM	Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum (GlobeNewswire)
Apr-24-24 04:05PM	Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting (GlobeNewswire) -5.83%
Apr-19-24 02:30PM	These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher? (InvestorPlace) +7.42%
Apr-16-24 08:50AM	Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength (Zacks)
Apr-12-24 06:40AM	7 A-Rated Aggressive Biotech Stocks to Bet On in 2024 (InvestorPlace)
Apr-02-24 08:00AM	Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (GlobeNewswire)
08:50AM	Loading…
Mar-15-24 08:50AM	What Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing' (Zacks)
Mar-14-24 09:38AM	12 Most Profitable Biotech Stocks To Invest In (Insider Monkey)
Mar-12-24 08:21AM	Corbus Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance) +16.46%
08:00AM	Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-06-24 08:00AM	Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit (GlobeNewswire)
Feb-28-24 08:00AM	Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer (GlobeNewswire) +7.40%
Feb-06-24 09:50AM	Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-02-24 04:01PM	Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-31-24 09:19AM	Corbus Pharmaceuticals Announces Pricing of Public Offering (GlobeNewswire) +5.29%
Jan-30-24 06:55PM	Corbus Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire) +35.12%
Jan-29-24 06:57AM	Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate (News Direct) -36.86%
Jan-26-24 07:30AM	CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024 (GlobeNewswire) +249.41%
Jan-23-24 08:00AM	Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU (GlobeNewswire)
Jan-09-24 08:00AM	Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti- v 8 monoclonal antibody (CRB-601) (GlobeNewswire)
Dec-18-23 08:00AM	Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU (GlobeNewswire)
09:40AM	Loading…
Dec-01-23 09:40AM	Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-07-23 09:56AM	Corbus Pharmaceuticals Reports Q3 2023 Financial Results with a Net Loss of $10.1 Million (GuruFocus.com) -16.67%
08:11AM	Corbus Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-23 08:00AM	Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti- V 8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting (GlobeNewswire)
Oct-17-23 08:00AM	Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023 (GlobeNewswire)
Oct-16-23 08:00AM	Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701 (GlobeNewswire)
Oct-03-23 08:00AM	Corbus Pharmaceuticals to Host Virtual 'Meet the Expert' Series (Session 2) on CRB-701 on October 10, 2023 (GlobeNewswire)
Sep-27-23 09:05AM	Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting (PR Newswire)
Sep-19-23 08:00AM	Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
Aug-08-23 09:08AM	Corbus Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Jul-31-23 08:00AM	Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference (PR Newswire) +9.09%
Jul-26-23 05:11PM	26 Biggest Marijuana Companies in the World (Insider Monkey)
Jun-26-23 08:00AM	Corbus Pharmaceuticals Set to Join Russell Microcap® Index (PR Newswire) -7.74%
May-31-23 08:00AM	Corbus Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference (PR Newswire) +6.76%
May-30-23 08:45PM	Oppenheimer Sees Over 50% Gains in These 2 Stocks Heres Why They Could Soar (TipRanks) -10.58%
May-09-23 08:11AM	Corbus Pharmaceuticals: Q1 Earnings Snapshot (AP Finance) -12.44%
08:00AM	Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
May-01-23 08:00AM	Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on CRB-601 av8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy Meeting (PR Newswire)
Apr-18-23 08:00AM	Corbus Pharmaceuticals Hosting Virtual 'Meet the Expert' Series: Blocking TGF with CRB-601--a New Play for an Old Target (PR Newswire) +14.72%
Apr-17-23 08:30AM	Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting (PR Newswire) +9.07%
Mar-14-23 04:35PM	Corbus Pharmaceuticals Data on CRB-601 av8 Blocking Antibody Accepted for Presentation at the America Association for Cancer Research Annual Meeting (PR Newswire) +36.44%
Mar-07-23 08:00AM	Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update (PR Newswire) -6.67%
Mar-06-23 08:00AM	Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA (PR Newswire)
Mar-02-23 08:00AM	Corbus Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference (PR Newswire) +5.36%
Feb-13-23 11:27AM	Corbus Pharma Expands Precision Oncology Pipeline With Addition Of Clinical-Stage Antibody Drug Conjugate (Benzinga) -11.06%
06:55AM	Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC) (PR Newswire)
Nov-10-22 09:05AM	Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (PR Newswire)
Nov-08-22 08:05AM	Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Nov-03-22 05:00PM	15 Best High Volume Penny Stocks to Buy Now (Insider Monkey)
Oct-14-22 08:05AM	Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (PR Newswire) -9.50%
Sep-26-22 08:05AM	Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors (PR Newswire) -6.38%
Sep-22-22 08:00AM	Corbus Presents First Pre-Clinical Data for CRB-913 at the European Association for the Study of Diabetes 2022 Annual Conference (PR Newswire)
Sep-12-22 07:00AM	Corbus Pharmaceuticals to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Aug-09-22 09:25AM	Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
May-11-22 08:00AM	Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference (PR Newswire) -8.18%
May-10-22 09:25AM	Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Apr-08-22 01:05PM	Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting (PR Newswire) -5.26%
Mar-31-22 09:51AM	Corcept (CORT) Posts OS Data from Phase II Ovarian Cancer Study (Zacks)
Mar-18-22 10:12AM	Zacks.com featured highlights include Carter's, Target Hospitality, iQIYI, The Buckle, and Corbus Pharmaceuticals (Zacks) -22.78%
Mar-17-22 10:41AM	Ride on Rising P/E Investing With These 5 Top-Ranked Stocks (Zacks)
Mar-11-22 08:05AM	Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference (PR Newswire) +5.00%
Mar-08-22 06:15PM	Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +7.06%
08:05AM	Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates (PR Newswire)
Mar-02-22 07:00AM	Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer (GlobeNewswire) +11.59%
Jan-14-22 09:38AM	Investors Financial Group, LLC Buys USHG Acquisition Corp, Daktronics Inc, Weber Inc, Sells MP ... (GuruFocus.com)
Jan-12-22 10:35AM	JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th (ACCESSWIRE) -6.95%
Dec-31-21 09:58AM	Here's Why You Should Hold Onto Acadia Healthcare (ACHC) Now (Zacks)
Dec-29-21 10:00AM	After Plunging 29.4% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) (Zacks)
Dec-07-21 10:00AM	Down 31.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Corbus Pharmaceuticals (CRBP) (Zacks) +5.54%
08:05AM	Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer (PR Newswire)
Nov-12-21 08:05AM	Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates (PR Newswire)
Nov-11-21 08:05AM	Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference (PR Newswire)
Nov-02-21 03:02PM	Will Corbus Pharmaceuticals (CRBP) Report Negative Q3 Earnings? What You Should Know (Zacks)
Oct-21-21 09:30AM	uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors (GlobeNewswire)
Sep-10-21 06:45AM	Could The Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Aug-12-21 09:45AM	Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.26%
08:05AM	Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates (GlobeNewswire)
Jul-29-21 03:04PM	Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks) -5.41%
Jun-24-21 08:05AM	Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis (GlobeNewswire)
Jun-21-21 05:48PM	Is Corbus Pharmaceuticals Holdings Inc (CRBP) A Good Stock To Buy? (Insider Monkey)
Jun-18-21 08:38AM	Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock? (Zacks)
Jun-12-21 04:19AM	We Think Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package Needs To Be Put Under A Microscope (Simply Wall St.)
Jun-03-21 02:42AM	Does Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Have A Healthy Balance Sheet? (Simply Wall St.)
Jun-02-21 06:19AM	This Biotech Penny Stock Is Better Than Dogecoin (Motley Fool)
Jun-01-21 12:26PM	Corbus In-Licenses Two Anti-Integrin Antibodies Targeting Cancer, Fibrotic Diseases Settings (Benzinga) -5.53%
07:05AM	Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases (GlobeNewswire)

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HOLMER ALAN F	Director	Jun 14 '24	Option Exercise	30.00	1,667	50,010	5,829	Jun 14 04:24 PM
Moran Sean F.	Chief Financial Officer	Apr 10 '24	Option Exercise	30.00	1,787	53,610	48,605	Apr 11 09:17 AM
Cormorant Asset Management, LP	10% Owner	Mar 08 '24	Buy	44.38	300,000	13,314,193	2,025,000	Mar 11 05:34 PM
Cormorant Asset Management, LP	10% Owner	Mar 07 '24	Buy	40.05	250,000	10,013,367	1,725,000	Mar 11 05:34 PM
Cormorant Asset Management, LP	10% Owner	Feb 02 '24	Buy	19.00	750,000	14,250,000	1,475,000	Feb 06 04:00 PM
Cohen Yuval	Chief Executive Officer	Jan 26 '24	Option Exercise	4.97	7,179	35,680	7,179	Jan 30 04:56 PM
HOLMER ALAN F	Director	Jan 26 '24	Option Exercise	4.97	629	3,126	1,379	Jan 30 06:07 PM
Cormorant Asset Management, LP	10% Owner	Jan 26 '24	Buy	32.24	282,632	9,111,941	725,000	Jan 30 04:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRBP

Corbus Pharmaceuticals Holdings Inc

Upgrade your FINVIZ experience